ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Sells $491,770.62 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam sold 7,414 shares of ANI Pharmaceuticals stock in a transaction on Monday, April 15th. The stock was sold at an average price of $66.33, for a total transaction of $491,770.62. Following the transaction, the chief operating officer now directly owns 825,206 shares in the company, valued at $54,735,913.98. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Muthusamy Shanmugam also recently made the following trade(s):

• On Wednesday, April 17th, Muthusamy Shanmugam sold 9,520 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.40, for a total transaction of $622,608.00.
• On Thursday, March 7th, Muthusamy Shanmugam sold 15,085 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.35, for a total transaction of $1,000,889.75.
• On Tuesday, March 5th, Muthusamy Shanmugam sold 10,093 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.35, for a total value of $659,577.55.
• On Monday, January 22nd, Muthusamy Shanmugam sold 5,692 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $55.95, for a total value of $318,467.40.
• On Thursday, January 18th, Muthusamy Shanmugam sold 9,784 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $55.30, for a total value of $541,055.20.

ANI Pharmaceuticals Price Performance

Shares of ANIP traded down $0.08 during midday trading on Wednesday, hitting $65.48. 123,206 shares of the company traded hands, compared to its average volume of 138,141. The stock has a 50-day moving average of $64.41 and a 200-day moving average of $58.47. ANI Pharmaceuticals, Inc. has a one year low of $36.99 and a one year high of $70.81. The firm has a market cap of $1.38 billion, a P/E ratio of 77.95 and a beta of 0.79. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.57 and a quick ratio of 2.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. The firm had revenue of $131.65 million for the quarter, compared to analysts’ expectations of $123.02 million. As a group, sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 3.55 EPS for the current fiscal year.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ANIP. Rubric Capital Management LP increased its position in shares of ANI Pharmaceuticals by 32.8% during the fourth quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock valued at $62,032,000 after buying an additional 277,989 shares during the period. Invesco Ltd. grew its holdings in shares of ANI Pharmaceuticals by 185.4% during the third quarter. Invesco Ltd. now owns 339,735 shares of the specialty pharmaceutical company’s stock worth $19,725,000 after purchasing an additional 220,690 shares in the last quarter. BlackRock Inc. grew its holdings in shares of ANI Pharmaceuticals by 9.9% during the second quarter. BlackRock Inc. now owns 2,133,100 shares of the specialty pharmaceutical company’s stock worth $114,825,000 after purchasing an additional 191,402 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of ANI Pharmaceuticals by 13.8% during the fourth quarter. Vanguard Group Inc. now owns 1,288,972 shares of the specialty pharmaceutical company’s stock worth $71,074,000 after purchasing an additional 156,594 shares in the last quarter. Finally, Balyasny Asset Management LLC purchased a new position in shares of ANI Pharmaceuticals during the third quarter worth about $4,466,000. 76.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ANIP has been the topic of a number of recent analyst reports. Guggenheim lifted their target price on ANI Pharmaceuticals from $70.00 to $77.00 and gave the stock a “buy” rating in a research note on Tuesday, March 5th. Capital One Financial initiated coverage on ANI Pharmaceuticals in a research note on Friday, March 15th. They issued an “overweight” rating and a $80.00 price objective on the stock. HC Wainwright boosted their price objective on ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a research note on Monday, March 4th. Finally, Truist Financial boosted their price objective on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $80.00.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.